drugset / Trial / NCT00233558

Open-Label Steroid Reduction Study of Adalimumab With Methotrexate in Patients With Active Rheumatoid Arthritis

NCT00233558

Phase 4 Terminated 160 enrolled Abbott
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to evaluate the clinical efficacy of scheduled versus free reduction of steroid treatment in patients with active RA treated with adalimumab + MTX

Timeline

Start
2005-06
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Background Adalimumab Monoclonal antibody 40 mg
Background Methotrexate Small molecule

Indications